Literature DB >> 12028020

Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology.

Duncan Gowans1, Alan O'Sullivan, Sara Rollinson, Phillipa Roddam, Mike Groves, Chris Fegan, Gareth Morgan, David Bowen.   

Abstract

An autoimmune mechanism in the pathogenesis of myelodysplastic syndrome (MDS) is suggested by response to immunosuppression, with CD8+ T-lymphocytes implicated in the haematopoietic suppression. We therefore sought evidence for human leucocyte antigen (HLA) restriction and variant frequency differences in selected polymorphisms at the loci for the immunomodulatory cytokines, tumour necrosis factor alpha (TNF-alpha), lymphotoxin-alpha (LT-alpha) and interleukin 10 (IL-10) in patients with MDS and acute myeloid leukaemia (AML) compared with normal controls. DNA from 150 MDS/AML patients [24 AML, 53 refractory anaemia (RA), 25 RA with excess blasts (RAEB), four RAEB in transformation (RAEBt), 21 sideroblastic leukaemia, 22 chronic myelomonocytic leukaemia] was screened. Control data was from Scottish blood donors (HLA class I/II), healthy General Practitioner-based subjects (TNF-alpha/LT-alpha) and published values (IL-10). HLA class I/II haplotypes were determined using sequence-specific primers. Polymorphisms were assayed at TNF-alpha -308, LT-alpha +252 and IL10 -824, -597 and -1082 loci. Variant frequencies of common haplotypes at HLA class I and II, high-/low-producer TNF-alpha/LT-alpha and IL-10 loci were not different between patients and controls or within the French-American-British, International Prognostic Scoring System or cytogenetic subgroups and were not associated with altered survival for MDS/AML patients. TNF2 allele frequency was greater in the MDS/AML cohort (chi2 = 6.593, P < 0.05) but the biological significance was uncertain in the absence of an increased high-producer TNF-alpha/LT-alpha haplotype frequency. We can find no genetic influence for these polymorphisms in HLA class I/II, TNF-alpha/LT-alpha and IL-10 loci on either predisposition or disease progression in MDS/AML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028020     DOI: 10.1046/j.1365-2141.2002.03452.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

Review 1.  Interleukin-10 polymorphisms, cancer susceptibility and prognosis.

Authors:  W Martin Howell; Matthew J Rose-Zerilli
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.

Authors:  Timothy R Morgan; Richard W Lambrecht; Herbert L Bonkovsky; Raymond T Chung; Deepa Naishadham; Richard K Sterling; Robert J Fontana; William M Lee; Marc G Ghany; Elizabeth C Wright; Thomas R O'Brien
Journal:  J Hepatol       Date:  2008-06-05       Impact factor: 25.083

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.